When are nausea and vomiting most frequent during zolbetuximab (Vyloy) treatment combined with fluoropyrimidine- and platinum-containing chemotherapy?

During zolbetuximab (Vyloy) treatment combined with fluoropyrimidine- and platinum-containing chemotherapy, nausea and vomiting occur most frequently in the first treatment cycle and decrease in incidence during subsequent cycles.